Want to see HK:9877 full AI Analyst Report?
Top Page
Jenscare Scientific Co. Ltd. Class H
(9877)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$7.50
▲(1.35% Upside)
Action:Reiterated
Date:06/27/26
The score is held down primarily by weak profitability and continued cash burn despite strong revenue growth and high gross margins. Technicals add pressure as the stock trades below all key moving averages with bearish MACD, although oversold readings provide some near-term stabilization potential. Valuation remains difficult to support given negative earnings and no indicated dividend yield.
Positive Factors
Commercialization and Gross Margin
The sharp revenue ramp shows that JensCare is progressing from development toward commercialization. A gross margin near 75% also indicates attractive product economics that could support future operating leverage as sales scale.
Negative Factors
Deep Net Losses
The substantial net loss indicates that current revenue is insufficient to cover the company’s operating cost base. Persistent losses could delay self-sustaining growth, require additional financing, and limit the strategic flexibility of the business.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercialization and Gross Margin
The sharp revenue ramp shows that JensCare is progressing from development toward commercialization. A gross margin near 75% also indicates attractive product economics that could support future operating leverage as sales scale.
Read all positive factors
Jenscare Scientific Co. Ltd. Class H (9877) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.16B
Dividend YieldN/A
Average Volume (3M)212.68K
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue Growth992.68%
EPS Growth35.04%
CountryHK
Employees195
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-0.44
Shares Outstanding310,306,200
10 Day Avg. Volume16,780
30 Day Avg. Volume212,679
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.22
Price to Sales (P/S)37.79
P/FCF Ratio-41.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)HK$261.02M
Jenscare Scientific Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Jenscare Scientific Co., Ltd. operates as a medical technology enterprise dedicated to advancing interventional therapies for structural heart conditions within the People's Republic of China. Among its pipeline, the company features LuX-Valve, an...
How the Company Makes Money
null...
Jenscare Scientific Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 88.24M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 66.60M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -210.22M | -202.04K | -429.68M | -504.82M | -501.77M |
| Net Income | -264.21M | -177.51K | -371.74M | -439.31M | -500.52M |
Balance Sheet | |||||
| Total Assets | 896.62M | 1.03B | 1.33B | 1.43B | 1.34B |
| Cash, Cash Equivalents and Short-Term Investments | 527.63M | 605.99M | 1.09B | 825.11M | 800.59M |
| Total Debt | 47.38M | 64.42M | 44.08M | 3.87M | 2.41M |
| Total Liabilities | 123.16M | 110.61M | 100.84M | 58.30M | 50.77M |
| Stockholders Equity | 789.75M | 931.76M | 1.23B | 1.37B | 1.29B |
Cash Flow | |||||
| Free Cash Flow | -80.08M | -288.81M | -300.64M | -208.03M | -157.25M |
| Operating Cash Flow | -75.00M | -217.55M | -222.44M | -158.48M | -141.89M |
| Investing Cash Flow | 5.96M | 5.59M | 358.13M | -146.58M | -475.07M |
| Financing Cash Flow | -20.61M | -110.74M | 56.44M | 188.93M | 1.08B |
Jenscare Scientific Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$5.56B | 12.63 | 13.24% | 2.36% | 16.15% | 31.89% | |
61 Neutral | HK$7.27B | 24.96 | 9.64% | 0.79% | 34.94% | 12.99% | |
59 Neutral | HK$5.98B | 92.65 | 1.72% | ― | 0.75% | -20.22% | |
59 Neutral | HK$2.86B | 28.37 | 4.06% | ― | 94.80% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$3.43B | -20.55 | -7.65% | ― | 21.23% | 36.89% | |
46 Neutral | HK$4.16B | -18.64 | -19.31% | ― | 992.68% | 35.04% |
* Healthcare Sector Average
HK:9877
Jenscare Scientific Co. Ltd. Class H
7.25
-1.26
-14.86%
HK:9996
Peijia Medical Ltd.
5.08
-2.63
-34.11%
HK:1302
LifeTech Scientific Corporation
1.38
-0.56
-28.87%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
33.06
0.42
1.28%
HK:1789
AK Medical Holdings Ltd.
5.00
-0.63
-11.12%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
6.70
-2.10
-23.86%
Jenscare Scientific Co. Ltd. Class H Corporate Events
Jenscare Scientific Schedules Board Meeting to Review 2026 Interim Results and Dividend Plan
Aug 19, 2026
Jenscare Scientific Co., Ltd. has scheduled a board meeting for August 31, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026 and to authorize their publication. The board will also consider whether...
Jenscare forecasts sharp interim revenue surge on heart device growth
Aug 10, 2026
Jenscare Scientific Co., Ltd., a mainland China-based medical device maker specializing in structural heart disease therapies, is seeing strong commercial traction for its Ken-Valve transcatheter aortic valve replacement system and related product...
Jenscare Marks Key Milestone in Global Trial for LuX-Valve Plus
Jul 16, 2026
Jenscare Scientific announced that its proprietary LuX-Valve Plus transvenous tricuspid valve replacement system has successfully completed implantation in the first batch of enrolled subjects in an FDA-approved pivotal registration trial. The dev...
Jenscare Wins EU MDR CE Mark for LuX-Valve Plus, Advancing Global Heart-Device Push
Jul 8, 2026
Jenscare Scientific Co., Ltd. announced that its proprietary transvenous tricuspid valve replacement system, LuX-Valve Plus, has obtained CE certification under the EU Medical Device Regulation, marking a key step in the group’s internationa...
Jenscare Wins Hong Kong Approval for Ken-Valve Heart Valve System
Jun 21, 2026
Jenscare Scientific Co., Ltd. has received approval from Hong Kong’s Department of Health for its Ken-Valve Transcatheter Aortic Valve Replacement System, a device designed to treat aortic regurgitation and combined aortic stenosis. The comp...
Jenscare Scientific Reports Poll Results and High Turnout at 2025 AGM
May 28, 2026
Jenscare Scientific Co., Ltd. held its 2025 annual general meeting in Ningbo, Zhejiang, with the board convening the session in compliance with PRC company law, Hong Kong listing rules, and the firm’s articles of association. All directors a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.